Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 6 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.

Uric acid tied to cardiometabolic risk factors in overweight, obese youths

14 Sep 2018

Uric acid is positively associated with blood pressure, insulin and triglycerides in overweight and obese youths, reports a study. A relevant clustering of metabolic risk factors occur as uric acid levels increase, while the risk factor that is less frequently present is elevated blood pressure (BP).

Among participants, boys had significantly higher uric acid than girls. Uric acid showed a positive, significant association with office, daytime and night-time systolic (S)BP, insulin, and triglycerides.

There was a progressive increment in body mass index (BMI), waist circumference, BMI z score, fasting insulin and HOMA index after stratification by sex-specific uric acid tertiles. Such increment was also observed in office and ambulatory SBP among boys.

Similarly, there was an increase in the number of abnormal metabolic risk factors with the uric acid values. The higher the number of metabolic components, the higher the uric acid values.

Furthermore, multiple regression analysis revealed that uric acid significantly correlated with male sex, waist circumference, both office and night-time SBP, and birth weight.

“Further studies need to assess the mechanistic link between uric acid and the cardiometabolic risk factors,” the authors said.

To examine the link between uric acid and individual cardiometabolic risk factors, as well as their degree of clustering, 333 Caucasians of both sexes (149 women; aged 5–18 years) who underwent an assessment of overweight/obesity were recruited. The authors measured anthropometric parameters, office and 24-hour BP measurement and metabolic profiles, including HDL-cholesterol, triglycerides, insulin, HOMA index and uric acid.

“Observational studies have indicated that high levels of serum uric acid are associated with the risk of cardiovascular disease,” the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 6 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.